Asset overview
Program snapshot
Target: CD22
Cell type: NK_CELL
Indications: Refractory B-Cell Lymphoma
Sponsor: Allife Medical Science and Technology Co., Ltd.
Institution: Allife Medical Science and Technology Co., Ltd.
Car Nk
Anti-CD22 CAR NK Cells
Anti-CD22 CAR NK Cells is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Allife Medical Science and Technology Co., Ltd., with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Early Phase1
Status: Unknown
Trial count: 1
Active trials: 0
First posted: October 2, 2018
Last updated: January 30, 2019
Signal summary
IP and BD posture
IP signal: Unlinked
BD label: Low Confidence
Confidence: Low
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation0
IP linkage0
Licensing clarity2
Strategic interest2
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT03692767